Drug search by name

Doxorubicin liposome Intravenous and Trastuzumab-dkst Intravenous

Determining the interaction of Doxorubicin liposome Intravenous and Trastuzumab-dkst Intravenous and the possibility of their joint administration.

Check result:

Doxorubicin liposome Intravenous <> Trastuzumab-dkst Intravenous

Relevance: 10.06.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Ask your doctor before using DOXOrubicin liposomal together with trastuzumab. This can cause damage to the heart. Heart function and drug levels in the blood may be monitored with blood tests during treatment. Call your doctor if you experience difficulty breathing, fluid retention, or chest pain. You may need a dose adjustment to safely take both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

GENERALLY AVOID: The use of trastuzumab and anthracyclines in combination has been associated with a high risk of cardiotoxicity. Trastuzumab and agents in the anthracycline class are individually cardiotoxic and may have additive effects during coadministration. Since trastuzumab has a half-life of approximately 28 to 38 days, it may persist in the circulation for up to 27 weeks after stopping treatment. Thus, the use of anthracyclines after stopping trastuzumab may also carry a higher risk of cardiac toxicity.

MANAGEMENT: Trastuzumab and cardiotoxic agents such as anthracyclines should not be used in combination except in settings where cardiac monitoring is possible. The use of anthracycline-based therapy should be avoided, if possible, for up to 7 months after stopping trastuzumab. If anthracyclines must be used sooner, the patient's cardiac function should be closely monitored.

References

Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
"Product Information. DOXOrubicin Hydrochloride (DOXOrubicin)." Pfizer U.S. Pharmaceuticals Group, New York, NY.
Strasser F, Betticher DC, Suter TM "Trastuzumab and breast cancer." N Engl J Med 345 (2001): 996
Cerner Multum, Inc. "Australian Product Information." O 0
"Product Information. Herceptin (trastuzumab)." Genentech, South San Francisco, CA.

Doxorubicin liposome Intravenous

Generic Name: doxorubicin liposomal

Brand name: Doxil, Lipodox, Lipodox 50

Synonyms: Doxorubicin liposomal, DOXOrubicin (Liposomal)

What is Doxorubicin liposome Intravenous?

Trastuzumab-dkst Intravenous

Generic Name: trastuzumab

Brand name: Herceptin, Kanjinti, Ogivri

Synonyms: Trastuzumab

What is Trastuzumab-dkst Intravenous?

+ Add a drug Remove all

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

The list of popular interactions